Assignee
MONTE ROSA THERAPEUTICS AG
CH·3 granted patents·4 pending applications·0 citations·filing 2022–2025
Top patents by PatentIndex Score
7 records- 0174US12257247B2Targeted degradation of VAV1MONTE ROSA THERAPEUTICS AG·Filed 2024·Granted Mar 25, 2025·0 cites·12 claims
- 0271US12391663B2Isoindolinone compoundsMONTE ROSA THERAPEUTICS AG·Filed 2023·Granted Aug 19, 2025·0 cites·20 claims
- 0368US12459920B2Targeted protein degradationMONTE ROSA THERAPEUTICS AG·Filed 2025·Granted Nov 4, 2025·0 cites·5 claims
- 0468US2025340528A1Targeted protein degradationMONTE ROSA THERAPEUTICS AG·Filed 2025·Application pending·0 cites
- 0553US2022242846A1Isoindolinone compoundsMONTE ROSA THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 0652US2025205219A1Targeted degradation of vav1MONTE ROSA THERAPEUTICS AG·Filed 2025·Application pending·0 cites
- 0751US2025263395A1Compounds that mediate protein degradation and methods of use thereofMONTE ROSA THERAPEUTICS AG·Filed 2025·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →